Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — H1 2024 Earnings Presentation
33 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, August 2024
Slide 1: 2024 Interim Results Presentation
Zylox-Tonbridge（2190.HK） 2024 Interim Results Presentation August 2024
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Business Highlights
Business Highlights Financial Sales R&D Industry leader of promoting 366 million RMB innovative ideas and techniques 8 Number of NMPA registration Revenue • Quickly expanded our hospital access for the approvals obtained in mid-2024 • The sales network covers more + 59.0% YOY Growth products by capt
Slide 4: Financial Highlights
Financial Highlights • High revenue growth, turn loses into profits
Slide 5: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth in 2022H1-2024H1 Overseas Sales Rise Sharply in 2022H1-2024H1 （in 000’ RMB） （in 000’ RMB） Gross Profit 75.6% 74.2% 71.3% Margin： 2022H1-2024H1CAGR：55% 365,990 2022H1-2024H1CAGR ：105% 59% 120,635 11,485 230
Slide 6: Neurovascular - Steady Revenue Growth
Neurovascular - Steady Revenue Growth Revenue of Neurovascular Products Main Source of Revenue （ in 000’ RMB） % of Revenue : 73.1% 72.1% 66.5% Thrombite SilverSnake Clot Retriever Intracranial Device Support Catheter 47% 243,510 Kylin Phoenix Baiju Flow Diverter Detachable Coil Intracranial 166,038
Slide 7: Peripheral-vascular - Rapid Revenue Growth
PTA球囊 Peripheral-vascular - Rapid Revenue Growth 扩张导管 Revenue of Peripheral-vascular Products Main Source of Revenue （ in 000’ RMB） Drug % of Revenue : 26.9% 27.9% 33.0% Retrievable Snare Coated Inferior Retrieval PTA Balloon Vena Cava Kit for IVC Catheter Filter Filter 120,635 Endovenous PTA Balloo
Slide 8: Increased Operational Efficiency in Line with Business Development
Increased Operational Efficiency in Line with Business Development Selling and Distribution Expenses R&D Expenses Administrative Expenses % of Revenue % of Revenue % of Revenue 95% 70% 54% 57% 57% ↓11% 50% ↓29% 42% 31% 33% 33% ↓10% 28% 22% 22% 22% 12% 2021A 2022A 2023A 2023H1 2024H1 2021A 2022A 2023
Slide 9: Trend of Profits Emerged with Improved Sales Scale and Efficiency
With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged Other Non-operating Income and Expenses Unadjusted Net Profit / (Loss ) （ in 000’ RMB） （ in 000’ RMB） 2022A 2023A 2024H1 2022H1 2023H1 2024H1 80,000 60,000 3,638 50,000 68,865 50,000 4,578 20,000
Slide 10: Sufficient Cash and Efficient Operations to Support Rapid Growth
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years Cash From Operating Activities 2024H1 Cash Status Trade Receivables Turnover （ in 000’ RMB） （ Turnover Days ） （ in 000’ RMB） 2,577,065 2,584,032 101,635 101,635 8,018 1136 0.8 0.8 0.7 -22,352 2022A 2023A 2024H1 (103
Slide 11: Sales and Marketing
Sales and Marketing • Extensive Sales Network and Rapid Commercialization Progress
Slide 12: Deeply Cultivate the Domestic Market, Strengthen Channel Advantage
Deeply Cultivate the Domestic Market, Continuing to Strengthen the Channel Advantage to Build an Extensive Sales Network Distributors Across the Country “同频共振 守正出奇”2024年归创通桥全国渠道发展论坛 Rapid Commercialization Capabilities Numbers of Provincial Procurement Platforms 1 that Newly Launched Products are In
Slide 13: Neurovascular Interventional Portfolio – Professional Academic Marketing Strategy
Neurovascular Interventional Portfolio – Professional Academic Marketing Strategy Doctor training support activities： • Covered 5 stroke centers in Changzhou, Beijing, Zhengzhou, Chenzhou and Kunming, including live surgery broadcast events, devices in vitro demonstration, fun running activities, et
Slide 14: Neurovascular Launched Key Product – Kylin Flow Diverter
Neurovascular Launched Key Product – Kylin Flow Diverter Participated in 10+ professional academic conferences, Conducted an international live surgery broadcast at Alice Neurointerventional Physician Forum Complete Occlusion Rate of Aneurysms at 12-month Post- procedure 88.15% Kylin Flow Diverter C
Slide 15: Peripheral-vascular Interventional Portfolio – Professional Academic Marketing Strategy
Peripheral-vascular Interventional Portfolio – Professional Academic Marketing Strategy Creation Of Brand「JINGLUN」For Peripheral Venous Communication Creation Of Brand「YUANXING」For Peripheral Artery Communication Active Participation in Professional Academic Conferences VINNOVA 2024 CAVS 2024 SJVF 2
Slide 16: Peripheral-vascular Launched Key Product – Penguin Peripheral Venous Stent System
Peripheral-vascular Launched Key Product – Penguin Peripheral Venous Stent System Active Participation in 14+ Professional Academic Conferences The patency rate of target vessels reached 100% at 12 months postoperatively Numbers of Provincial Procurement Platforms 26 Proximal beveled port, tapered t
Slide 17: Peripheral-vascular Launched Key Product – Unicorn Suture-mediated Closure System
Peripheral-vascular Launched Key Product – Unicorn Suture-mediated Closure System 1 According to the forecast, the annual number vascular closure procedures in China was about 0.28 million and it is expected to reach 3.78 million by 2030, with a CAGR of 26.9%. Effectively simplify and accelerate the
Slide 18: Continued to Grow International Business and Further Enhanced our Brand Awareness
Continued to Grow International Business and Further Enhanced our Brand Awareness Products Approved in Overseas Markets “同频共振 守正出奇”2024年归创通桥全国渠道发展论坛 Commercialized in 22 Countries/Regions 遍布全国的经销商充分发挥渠道优势 ➢ Accelerate overseas layout, centering on Europe, Product Approved Region further expanding in
Slide 19: Several Products Have Proven Their Clinical Application Value Overseas
Several Products Have Proven Their Clinical Application Value Overseas 遍布全国的经销商充分发挥渠道优势 1 Three-Year Results of Turkish Clinical Study of Thrombite thrombectomy device Released ➢ The study was a retrospective analysis of 525 patients who were included in the Turkish Interventional Neurology database
Slide 20: Embraced VBPs and Increased Products' Market Penetration
Leveraging a differentiated and comprehensive product portfolio, Embraced VBPs and increased products’ market penetration Beijing-Tianjin-Hebei Dummy E “3+N” Alliance VBP Hebei-Sanming Dummy D Alliance VBP ✓ Clot Retriever Device: won the bid in Group A and won the first place in Group The Henan Pub
Slide 21: R&D
21 R&D • Advance R&D with great efficiency steadily and innovatively
Slide 22: Rich and Comprehensive Product Portfolio to Meet Huge Clinical Demand
Rich and Comprehensive Product Portfolio to Meet Huge Clinical Demand Intracranial Ischemic Stroke Peripheral Artery Disease Procedure Volume： 110,000 units（2023） Procedure Volume： 170,000 units（2023） BADDASS ： Clot Retriever Device + Support Catheter + BGC PTA Balloon（Normal 、High Pressure） + DCB +
Slide 23: Neurovascular Interventional Portfolio – 29 Products
Neurovascular Interventional Portfolio – 29 Products 23 Approved Products 6 Products 2020 2021-2022 2023 2024 2025 2026 2027 2 Approved 9 Approved 8 Approved 4 Approved 2 Approved 3 Approved 1 Approved Intracranial Ischemic Thrombite Clot Microcatheter Stroke Balloon Guiding Retriever Device Cathete
Slide 24: Neurovascular Interventional Portfolio – Future Key Products
Neurovascular Interventional Portfolio – Future Key Products Embolization Assist Stent Drug Coated Self-expandable Intracranial Stent Self-expandable Intracranial Stent Rapamycin • Indications ✓ Intracranial Hemorrhagic Stroke. It is often used in combination with a coil for the • Indications surgic
Slide 25: Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio – 34 Products
Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio – 34 Products 21 Approved Products 12 Products 2020 2021-2022 2023 2024 2025 2026 2027 2028 4 Approved 4 Approved 9 Approved 4 Approved 5 Products 4 Products 2 Products 1 Product Balloon Tigereye ST 1 Expandable 1 1 Covered St
Slide 26: Peripheral-Vascular Interventional Portfolio – Future Key Products
Peripheral-Vascular Interventional Portfolio – Future Key Products OCT-guided Peripheral-Vascular Targeted Multi-spot Stent System Atherectomy Catheter-Avinger Series Balloon Expandable Covered Stent “同频共振 守正出奇”2024年归创通桥全国渠道发展论坛 • Indications • Indications • Indications ✓ Stenotic and/or occlusive l
Slide 27: Prospects
y UF GUA ZYLOX-TONBRIDGE eitive DOOTCU | Sa inn!) Prospects
Slide 28: Building on our industry leadership in 2024, Become China's Leading Minimally Invasive Medical Device Company
Building on our industry leadership in 2024 Optimize product portfolio and Continued expansion of product accelerate innovation based on market share based on solid clinical needs commercialization capabilities • Optimize product portfolio by exploring clinical • Provide the market with differentiat
Slide 29: Thank you
Thank you Please refer to 2024 Interim Results Announcement for further information Click to download the 2024 Interim Results Announcement
Slide 30: Financial Reports
y UF GUA ZYLOX-TONBRIDGE Financial Reports
Slide 31: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 Six months ended June 30 RMB’000 2021 % of Revenue 2022 % of Revenue 2023 % of Revenue 2023 % of Revenue 2024 % of Revenue Revenue 177,912 100% 334,090 100% 527,754 100% 230,131 100% 365,990 100% Cost of sales -46,031 -26% -81,421 -24%
Slide 32: Consolidated Balance Sheet
Consolidated Balance Sheet Six months ended Year ended December 31 June 30 RMB’000 2021 2022 2023 2024 Non-current assets Property, plant and equipment 178,270 290,243 538,540 615,262 Right-of-use assets 34,115 48,136 39,820 39,742 Intangible assets 4,889 9,637 9,686 34,721 Prepayments and other rec
Slide 33: Consolidated Balance Sheet
Consolidated Balance Sheet Six months ended Year ended December 31 June 30 RMB’000 2021 2022 2023 2024 Non-current liabilities Deferred revenue 0 0 8,674 15,885 Lease liabilities 6,509 7,459 1,859 2,366 Total non-current liabilities 6,509 7,459 10,533 18,251 Current liabilities Trade and other payab
Zylox-Tonbridge Medical Technology — H1 2024 Earnings Presentation on 6ix